MannKind Corp. (NASDAQ:MNKD)‘s stock had its “underweight” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a research note issued to investors on Friday.

Other equities research analysts have also recently issued reports about the stock. S&P Equity Research decreased their price objective on shares of MannKind Corp. from $0.84 to $0.70 in a research report on Wednesday, August 31st. Piper Jaffray Cos. set a $0.10 price objective on shares of MannKind Corp. and gave the stock a “sell” rating in a research report on Sunday, August 21st. Four equities research analysts have rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $1.23.

Analyst Recommendations for MannKind Corp. (NASDAQ:MNKD)

MannKind Corp. (NASDAQ:MNKD) opened at 0.65 on Friday. MannKind Corp. has a 12 month low of $0.41 and a 12 month high of $2.60. The company’s market capitalization is $310.94 million. The stock’s 50 day moving average is $0.54 and its 200-day moving average is $0.87.

MannKind Corp. (NASDAQ:MNKD) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.31. The firm had revenue of $162.35 million for the quarter, compared to analyst estimates of $2 million. On average, analysts expect that MannKind Corp. will post ($0.11) EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors raised its position in MannKind Corp. by 6.1% in the first quarter. BlackRock Fund Advisors now owns 11,641,028 shares of the biopharmaceutical company’s stock worth $18,742,000 after buying an additional 673,881 shares during the period. A.R.T. Advisors LLC raised its position in MannKind Corp. by 22.9% in the first quarter. A.R.T. Advisors LLC now owns 710,077 shares of the biopharmaceutical company’s stock worth $1,143,000 after buying an additional 132,238 shares during the period. Bank of New York Mellon Corp raised its position in MannKind Corp. by 22.0% in the second quarter. Bank of New York Mellon Corp now owns 1,372,029 shares of the biopharmaceutical company’s stock worth $1,592,000 after buying an additional 247,858 shares during the period. California State Teachers Retirement System raised its position in MannKind Corp. by 30.1% in the second quarter. California State Teachers Retirement System now owns 679,996 shares of the biopharmaceutical company’s stock worth $789,000 after buying an additional 157,330 shares during the period. Finally, Commerzbank Aktiengesellschaft FI raised its position in MannKind Corp. by 2.6% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 129,291 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 3,309 shares during the period. 19.01% of the stock is currently owned by hedge funds and other institutional investors.

MannKind Corp. Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

5 Day Chart for NASDAQ:MNKD

Receive News & Stock Ratings for MannKind Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corp. and related stocks with our FREE daily email newsletter.